Common Contracts

17 similar Executive Employment Agreement contracts by Neumora Therapeutics, Inc.

NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT
Executive Employment Agreement • March 3rd, 2025 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances) • Nevada

This Executive Employment Agreement (the “Agreement”) is entered into between Neumora Therapeutics, Inc., a Delaware corporation (the “Company”), and Paul L. Berns (“Executive” and, together with the Company, the “Parties”) effective as of February 14, 2025 (the “Effective Date”). This Agreement supersedes in its entirety the Executive Chairman Agreement between Executive and the Company dated as of July 3, 2023 (the “Prior Agreement”).

NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT
Executive Employment Agreement • March 3rd, 2025 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances) • Arizona

This Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation (the “Company”), and Bill Aurora, Pharm.D. (“Executive” and, together with the Company, the “Parties”) effective as of February 14, 2025 (the “Effective Date”). This Agreement supersedes in its entirety the Executive Employment Agreement between Executive and the Company dated as of April 11, 2022 (the “Prior Agreement”).

NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT
Executive Employment Agreement • March 3rd, 2025 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances) • Massachusetts

This Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation (the “Company”), and Joshua Pinto, Ph.D. (“Executive” and, together with the Company, the “Parties”) effective as of February 14, 2025 (the “Effective Date”). This Agreement supersedes in its entirety the Executive Employment Agreement between Executive and the Company dated as of April 11, 2022 (the “Prior Agreement”).

NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT
Executive Employment Agreement • March 3rd, 2025 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances)

This Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation (the “Company”), and Robert Lenz, M.D., Ph.D. (“Executive” and, together with the Company, the “Parties”) effective as of August 31, 2023 (the “Effective Date”).

NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT
Executive Employment Agreement • March 3rd, 2025 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances)

This Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation (the “Company”), and Michael Milligan (“Executive” and, together with the Company, the “Parties”) effective as of February 14, 2025 (the “Effective Date”).

NEUMORA THERAPEUTICS, INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT
Executive Employment Agreement • March 7th, 2024 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances) • California

This Amended and Restated Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation f/k/a RBNC Therapeutics, Inc. (the “Company”), and Carol Y. Suh (“Executive” and, together with the Company, the “Parties”) effective as of January 1, 2023 (the “Effective Date”). This Agreement supersedes in its entirety that certain Executive Employment Agreement between Executive and the Company dated as of April 11, 2022 (the “Prior Agreement”).

NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT
Executive Employment Agreement • March 7th, 2024 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances)

This Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation (the “Company”), and Jason Duncan (“Executive” and, together with the Company, the “Parties”) effective as of November 13, 2023 (the “Effective Date”).

NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT
Executive Employment Agreement • August 25th, 2023 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances)

This Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation f/k/a RBNC Therapeutics, Inc. (the “Company”), and Joshua Pinto (“Executive” and, together with the Company, the “Parties”) effective as of April 11, 2022 (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of May 7, 2021 (the “Prior Agreement”).

NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT
Executive Employment Agreement • August 25th, 2023 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances)

This Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation f/k/a RBNC Therapeutics, Inc. (the “Company”), and [________] (“Executive” and, together with the Company, the “Parties”) effective as of April __, 2022 (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of [_______] (the “Prior Agreement”).

NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT
Executive Employment Agreement • August 25th, 2023 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances)

This Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation f/k/a RBNC Therapeutics, Inc. (the “Company”), and Paul Berns (“Executive” and, together with the Company, the “Parties”) effective as of April 11, 2022 (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of January 17, 2020 (the “Prior Agreement”).

NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT
Executive Employment Agreement • August 25th, 2023 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances)

This Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation f/k/a RBNC Therapeutics, Inc. (the “Company”), and John Dunlop (“Executive” and, together with the Company, the “Parties”) effective as of April 11, 2022 (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of January 17, 2020 (the “Prior Agreement”).

NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT
Executive Employment Agreement • August 25th, 2023 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances)

This Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation f/k/a RBNC Therapeutics, Inc. (the “Company”), and [ ] (“Executive” and, together with the Company, the “Parties”) effective as of April __, 2022 (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of [ ] (the “Prior Agreement”).

NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT
Executive Employment Agreement • June 30th, 2023 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances)

This Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation f/k/a RBNC Therapeutics, Inc. (the “Company”), and Joshua Pinto (“Executive” and, together with the Company, the “Parties”) effective as of April 11, 2022 (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of May 7, 2021 (the “Prior Agreement”).

NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT
Executive Employment Agreement • June 30th, 2023 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances)

This Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation f/k/a RBNC Therapeutics, Inc. (the “Company”), and John Dunlop (“Executive” and, together with the Company, the “Parties”) effective as of April 11, 2022 (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of January 17, 2020 (the “Prior Agreement”).

NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT
Executive Employment Agreement • June 30th, 2023 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances)

This Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation f/k/a RBNC Therapeutics, Inc. (the “Company”), and Paul Berns (“Executive” and, together with the Company, the “Parties”) effective as of April 11, 2022 (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of January 17, 2020 (the “Prior Agreement”).

NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT
Executive Employment Agreement • May 2nd, 2022 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances)

This Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation f/k/a RBNC Therapeutics, Inc. (the “Company”), and [ ] (“Executive” and, together with the Company, the “Parties”) effective as of April __, 2022 (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of [ ] (the “Prior Agreement”).

NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT
Executive Employment Agreement • May 2nd, 2022 • Neumora Therapeutics, Inc. • Biological products, (no disgnostic substances)

This Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation f/k/a RBNC Therapeutics, Inc. (the “Company”), and [________] (“Executive” and, together with the Company, the “Parties”) effective as of April __, 2022 (the “Effective Date”). This Agreement supersedes in its entirety that certain offer letter between Executive and the Company dated as of [_______] (the “Prior Agreement”).